See more : Extendicare Inc. (EXETF) Income Statement Analysis – Financial Results
Complete financial analysis of Provention Bio, Inc. (PRVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Provention Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Alderon Iron Ore Corp. (AXXDF) Income Statement Analysis – Financial Results
- Xingfa Aluminium Holdings Limited (0098.HK) Income Statement Analysis – Financial Results
- Worry Free Holdings Company (WYCC) Income Statement Analysis – Financial Results
- BNP Paribas SA (BNPQY) Income Statement Analysis – Financial Results
- Brampton Brick Limited (BBL-A.TO) Income Statement Analysis – Financial Results
Provention Bio, Inc. (PRVB)
About Provention Bio, Inc.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 12.90M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 512.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.38M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 96.03% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 75.80M | 69.63M | 66.36M | 36.36M | 22.65M | 7.68M |
| General & Administrative | 64.11M | 47.35M | 33.33M | 8.01M | 4.17M | 1.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 64.11M | 47.35M | 33.33M | 8.01M | 4.17M | 1.46M |
| Other Expenses | 627.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 140.54M | 116.97M | 99.69M | 44.37M | 26.81M | 9.14M |
| Cost & Expenses | 141.06M | 116.97M | 99.69M | 44.37M | 26.81M | 9.14M |
| Interest Income | 2.24M | 146.00K | 583.00K | 1.09M | 669.00K | 131.50K |
| Interest Expense | 1.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.47M | 387.00K | 33.00K | -16.00K | 149.00K | 6.50K |
| EBITDA | -124.69M | -115.58M | -99.69M | -44.37M | -26.67M | -9.13M |
| EBITDA Ratio | -966.98% | -8,285.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -128.16M | -115.58M | -99.69M | -44.37M | -26.81M | -9.14M |
| Operating Income Ratio | -993.88% | -8,285.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.20M | 146.00K | 583.00K | 1.09M | 149.00K | 6.50K |
| Income Before Tax | -126.96M | -115.43M | -99.10M | -43.29M | -26.67M | -9.13M |
| Income Before Tax Ratio | -984.54% | -8,274.70% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -13.39M | -1.00M | -523.00K | -1.09M | -187.00K | -131.50K |
| Net Income | -113.57M | -114.43M | -98.58M | -42.20M | -26.48M | -9.13M |
| Net Income Ratio | -880.69% | -8,203.01% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.52 | -1.81 | -1.88 | -1.04 | -1.18 | -0.27 |
| EPS Diluted | -1.52 | -1.81 | -1.88 | -1.04 | -1.18 | -0.27 |
| Weighted Avg Shares Out | 74.72M | 63.10M | 52.46M | 40.75M | 22.44M | 33.88M |
| Weighted Avg Shares Out (Dil) | 74.72M | 63.10M | 52.46M | 40.75M | 22.44M | 33.88M |
Provention Bio, Inc. (PRVB) Upgraded to Buy: What Does It Mean for the Stock?
How Much Upside is Left in Provention Bio, Inc. (PRVB)? Wall Street Analysts Think 187%
Provention Bio Puts Type 1 Diabetes to the Test with Pledge Campaign for Diabetes Awareness Month
Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2021 Results - Earnings Call Transcript
Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer
Provention Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
Provention Bio Reveals Early Data For Coxsackievirus B Vaccine Candidate
Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
Provention Bio to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021
Source: https://incomestatements.info
Category: Stock Reports